ARO DIMER PA
Alternative Names: ARO-DIMER-PALatest Information Update: 20 Jan 2026
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antihyperlipidaemics; Small interfering RNA
- Mechanism of Action APOC3 protein expression inhibitors; PCSK9 protein expression inhibitors; RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Hyperlipoproteinaemia type V
Most Recent Events
- 22 Dec 2025 Phase-I/II clinical trials in Hyperlipoproteinaemia type V in New Zealand (SC) (NCT07223658)
- 03 Nov 2025 Arrowhead Pharmaceuticals plans a phase I/II trial for Hyperlipoproteinaemia type V (SC, Injection) in December 2025 (NCT07223658)
- 10 Oct 2025 Pharmacodynamics data from preclinical trial in Hyperlipoproteinaemia type V released by Arrowhead Pharmaceuticals, before October 2025